Human C1-esterase inhibitor

Background: C1 Esterase Inhibitor (Human) is composed of purified endogenous complement component-1 esterase inhibitor (hC1INH) isolated from human plasma. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways.

This drug is indicated for prophylaxis and treatment of Hereditary Angioedema (HAE), a human genetic disorder caused by a shortage of C1 inhibitor activity that results in an overreaction of the immune system. The disease is characterized by acute attacks of painful, and in some cases, fatal swelling of several soft tissues or edema, which may last up to five days when untreated.

Indication: Intravenous and subcutaneous formulations of the human C1-esterase inhibitor are indicated for routine prophylaxis against acute attacks of hereditary angioedema in patients six years of age and older. It is also used to treat these in adult and adolescent patients with hereditary angioedema.

Associated Conditions: Acute attacks of hereditary angioedema, Acute attack of hereditary angioedema of the Abdomen, Acute attack of hereditary angioedema of the Larynx, Acute attack of hereditary angioedema of the face

Evaluation of the Effects of Bradykinin Antagonists on Pulmonary Manifestations of COVID-19 Infections (AntagoBrad-Cov Study).

Phase 2

Completed

Interventions: Drug: C1 Inhibitor Human
Other: Placebo
Drug: Icatibant Injection

Phase 1

Completed

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States

Phase 3

Completed

Interventions: Drug: Berinert
Drug: Cortisone acetate
Drug: Clemastin
Drug: NaCl

Locations: 🇩🇪
Kath. Klinikum Bochum, Med. Klinik III, Bochum, Germany
🇩🇪
Ludwig-Maximilian-Universität, München, Germany
🇩🇪
Klinikum rechts der Isar, Hals-Nasen-Ohren Klinik, München, Germany

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.